Relypsa, Inc., a clinical-stage biopharmaceutical company, announced today the recent appointment of two industry veterans to serve on the company’s board of directors: Paul J. Hastings, President and CEO of OncoMed Pharmaceuticals, and David W.J. McGirr, Senior Vice President and Chief Financial Officer of Cubist Pharmaceuticals.